Spero Therapeutics
SPRO
52 hedge funds and large institutions have $56M invested in Spero Therapeutics in 2018 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 17 increasing their positions, 14 reducing their positions, and 10 closing their positions.
21% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 14
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
2% less funds holding
Funds holding: 53 → 52 (-1)
6.29% less ownership
Funds ownership: 59.16% → 52.87% (-6.3%)
10% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 10
50% less capital invested
Capital invested by funds: $113M → $56M (-$57M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Aquilo Capital Management
San Francisco,
California
|
+$1.88M |
| 2 |
FI
Fosun International
Hong Kong,
China
|
+$1.31M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$641K |
| 4 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$281K |
| 5 |
Renaissance Technologies
New York
|
+$250K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$9.38M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
-$5.22M |
| 3 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$2.38M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$2.37M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.05M |
SPRO Hedge Fund Activity: Q4 2018 in Review
52 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Spero Therapeutics (SPRO) for Q4 2018, worth a combined $56M — down 50% from $113M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of SPRO and 9 opened new positions — a net loss of 1 holder — while 14 trimmed existing stakes and 17 added.
The largest buyer was Aquilo Capital Management, adding an estimated $1.88M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $9.38M sold.
- 52 institutional investors held Spero Therapeutics (SPRO) as of Q4 2018, down from 53 in Q3 2018.
- Funds reported $56M of Spero Therapeutics stock for Q4 2018, down 50% quarter-over-quarter.
- 9 funds opened new Spero Therapeutics positions in Q4 2018 and 10 closed out, a net change of -1 holder.
- The largest Spero Therapeutics buyer in Q4 2018 was Aquilo Capital Management, an estimated $1.88M added.
- The largest Spero Therapeutics seller in Q4 2018 was EcoR1 Capital, an estimated $9.38M sold.
Based on aggregated 13F filings for Q4 2018.